Valion Bio is a biotech developing Entolimod, a drug candidate for radiation sickness, plus a CDMO service arm that manufactures for other companies.
No revenue is reported; the company loses money on operations, with a net margin of -229.23% and an operating margin of -164.72% in the latest quarter.
Its TLR5 agonist platform is unique, but competitors like AstraZeneca and Novartis have deeper pipelines and resources, making the moat weak as the drug is unproven and the CDMO business faces intense competition.
None yet
None yet
Discussion heat is rising, but there are not enough posts yet to summarize. You can open the market-wide stock page.
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
